

## Choice of Oral & Poster Presentations

*See video statement Sacha Rothschild at the bottom of the page discussing the first 9 studies mentioned below:*

*Edward B. Garon, Matthew David Hellmann, Enric Carcereny Costa, Natasha B. Leighl, et al.*

[Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. | 2019 ASCO Annual Meeting Abstracts](#)

**Conclusions:** In KEYNOTE-001, 5-y OS rate was 23.2% in treatment-naïve pts and 15.5% in previously treated pts with advanced NSCLC treated with pembro, compared to a historical rate of ~5% (per SEER 2008–2014), prior to the introduction of anti-PD-1 therapy. 5-y OS rate was at least 25% in pts with PD-L1 TPS ≥50% in both pt populations in KEYNOTE-001. Clinical trial information: [NCT01295827](#)

OS by PD-L1 TPS.

	n	Median OS (95% CI), mo	36-mo OS rate, %	60-mo OS rate, %
Treatment-naïve	101*	22.3 (17.1–32.3)	37.0	23.2
- TPS ≥50%	27	35.4 (20.3–63.5)	48.1	29.6
- TPS 1%–49%	52	19.5 (10.7–26.3)	27.5	15.7
Previously treated	449 <sup>†</sup>	10.5 (8.6–13.2)	20.9	15.5
- TPS ≥50%	138	15.4 (10.6–18.8)	30.4	25.0
- TPS 1%–49%	168	8.5 (6.0–12.6)	16.9	12.6